The effects of aromatase inhibitors on lipids and thrombosis

British Journal of Cancer

Volumn 93, Issue , 2005, Pages S23-S27

  Bundred, N J ^a  

^a MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Aromatase inhibitors; Lipids; Tamoxifen; Thromboembolic events

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; EXEMESTANE; LETROZOLE; LIPID; MEGESTROL ACETATE; TAMOXIFEN;

ARTICLE; BREAST CANCER; CLINICAL TRIAL; DRUG BINDING; DRUG EFFECT; DRUG SAFETY; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; NONHUMAN; PRIORITY JOURNAL; THROMBOSIS; BLOOD; BREAST TUMOR; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CHEMICALLY INDUCED DISORDER; FEMALE; REVIEW; RISK FACTOR; THROMBOEMBOLISM;

AROMATASE INHIBITORS; BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; CEREBROVASCULAR ACCIDENT; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; LIPIDS; RISK FACTORS; THROMBOEMBOLISM;

EID: 24944494988     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602692     Document Type: Article

References (43)

1. ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists’ Group (2002) Anastrozole alone or in combination with tamoxifen vs tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359: 2131-2139
2. Atalay G, Dirix L, Biganzoli L, Beex L, Nooij M, Cameron D, Lohrisch C, Cufer T, Lobelle JP, Mattiaci MR, Piccart M, Paridaens R (2004) The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, ‘Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients’. Ann Oncol 15: 211-217
3. Boccardo F, Rubagotti A, Amoroso D, Mesiti M, Massobrio M, Benedetto C, Porpiglia M, Rinaldini M, Paladini G, Distante V, Franchi R, Failla G, Bordonaro R, Sismondi P, on Behalf of the Italian Tamoxifen Arimidex (ITA) Trial (2003) Anastrozole appears to be superior to tamoxifen in women already receiving adjuvant tamoxifen in women already receiving adjuvant tamoxifen treatment. 26th Annual San Antonio Breast Cancer Symposium; 3-6 December 2003: San Antonio, Texas. Abstract 3
4. Bushnell CD, Goldstein LB (2004) Risk of ischemic stroke with tamoxifen treatment for breast cancer. A meta-analysis. Neurology 63: 1230-1233
5. Campos H, McNamara JR, Wilson PW, Ordovas JM, Schaefer EJ (1988) Differences in low density lipoprotein subfractions and apolipoproteins in premenopausal and postmenopausal women. J Clin Endocrinol Metab 67: 30-35
6. Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, Jones SE, Alvarez I, Bertelli G, Ortmann O, Coates AS, Bajetta E, Dodwell D, Coleman RE, Fallowfield LJ, Mickiewicz E, Andersen J, Lonning PE, Cocconi G, Stewart A, Stuart N, Snowdon CF, Carpentieri M, Massimini G, Bliss JM, Intergroup Exemestane Study (2004) A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350: 1081-1092
7. Cushman M, Costantino JP, Tracy RP, Song K, Buckley L, Roberts JD, Krag DN (2001) Tamoxifen and cardiac risk factors in healthy women. Suggestion of an anti-inflammatory effect. Arterioscler Thromb Vasc Biol 21: 255-261
8. Danesh J, Collins R, Peto R (2000) Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 102: 1082-1085
9. De Aloysio D, Gambacciani M, Meschia M, Pansini F, Bacchi Modena A, Bolis PF, Massobrio M, Maiocchi G, Peruzzi E (1999) The effect of menopause on blood lipid and lipoprotein levels. The Icarus Study Group. Atherosclerosis 147: 147-153
10. Decensi A, Bonanni B, Guerrieri-Gonzaga A, Gandini S, Robertson C, Johansson H, Travaglini R, Sandri MT, Tessadrelli A, Farante G, Salinaro F, Bettega D, Barreca A, Boyle P, Costa A, Veronesi U (1998) Biologic activity of tamoxifen at low doses in healthy women. J Natl Cancer Inst 90: 1461-1467
11. Dewar J, Nabholtz JM, Bonneterre J, Buzdar A, Robertson JFR, Thurlimann B, Clark G (2000) The effect of anastrozole (Arimidex) on plasma lipids-data from a randomised comparison of anastrozole vs tamoxifen in postmenopausal women with advanced breast cancer. Breast Cancer Res Treat 64: 51 (Abstract 164)
12. Do KA, Green A, Guthrie JR, Dudley EC, Burger HG, Dennerstein L (2000) Longitudinal study of risk factors for coronary heart disease across the menopausal transition. Am J Epidemiol 151: 584-593
13. Dombernowsky P, Smith I, Falkson G, Leonard R, Panasci L, Bellmunt J, Bezwoda W, Gardin G, Gudgeon A, Morgan M, Fornasiero A, Hoffmann W, Michel J, Hatschek T, Tjabbes T, Chaudri HA, Hornberger U, Trunet PF (1998) Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 16: 453-461
14. Dziewulska-Bokiniec A, Wojtacki J, Skokowski J, Kortas B (1994) The effect of tamoxifen treatment on serum cholesterol fractions in breast cancer women. Neoplasma 41: 13-16
15. Elisaf M, Bairaktari E, Nicolaides C, Fountzilas G, Tzallas C, Siamopoulos K, Tsolas O, Pavlidis N (1996) The beneficial effect of tamoxifen on serum lipoprotein-A levels: an additional anti-atherogenic property. Anticancer Res 16: 2725-2728
16. Elisaf MS, Bairaktari ET, Nicolaides C, Kakaidi B, Tzallas CS, Katsaraki A, Pavlidis NA (2001) Effect of letrozole on the lipid profile in postmenopausal women with breast cancer. Eur J Cancer 37: 1510-1513
17. Goss PE, Grynpas MD, Josse R (2001) The effects of the steroidal aromatase inactivator exemestane on bone and lipid metabolism in the ovariectomized rat. Breast Cancer Res Treat 69: 224 (Abstract 132)
18. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Therasse P, Palmer MJ, Pater JL (2003) A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349: 1793-1802
19. Grey AB, Stapleton JP, Evans MC, Reid IR (1995) The effect of the antiestrogen tamoxifen on cardiovascular risk factors in normal postmenopausal women. J Clin Endocrinol Metab 80: 3191-3195
20. Harper-Wynne C, Ross G, Sacks N, Dowsett M (2001) Effects of the aromatase inhibitor letrozole on breast cell proliferation and bone/lipid indices in healthy postmenopausal women: pilot prevention study. Breast Cancer Res Treat 69: 225 (Abstract 136)
21. Hozumi Y, Saito T, Inoue K, Shiozawa M, Omoto Y, Tabei T, Nagai H (2004) Effects of anastrozole on the lipid profile in postmenopausal breast cancer patients-a preliminary study. Fourth European Breast Cancer Conference; 16-20 March 2004; Hamburg, Germany. Abstract 300
22. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E (1998) Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 280: 605-613
23. Kannel WB (1987) Metabolic risk factors for coronary heart disease in women: perspective from the Framingham Study. Am Heart J 114: 413-419
24. Kataja V, Hietanen P, Joensuu H, Ala-Luhtala T, Asola R, Kokko R, Holli K (2002) The effects of adjuvant anastrozole, exemestane, tamoxifen, and toremifene on serum lipids in postmenopausal women with breast cancer-a randomised study. 25th San Antonio Breast Cancer Symposium; 11-14 December 2002; San Antonio, Texas. Abstract 634
25. Korhonen T, Savolainen MJ, Ikäheimo M, Linnaluoto MK, Kervinen K, Kesäniemi YA (1996) Association of lipoprotein cholesterol and triglycerides with the severity of coronary artery disease in men and women. Atherosclerosis 127: 213-220
26. Krag LE, Geisler J, Lonning PE, Ottestad L, Risberg T, Hagen AI, Lien EA, Polli A, Paolini J, Massimini G (2004) Lipid and coagulation profile in postmenopausal women with early breast cancer at low risk treated with exemestane: a randomised, placebo-controlled study. American Society of Clinical Oncology; 5-8 June 2004; New Orleans, USA. Abstract 650
27. La Rosa JC (1997) Triglycerides and coronary risk in women and the elderly. Arch Intern Med 157: 961-968
28. Levi F, Randimbison L, Te VC, La Vecchia C (2002) Long-term mortality of women with a diagnosis of breast cancer. Oncology 63: 266-269
29. Love RR, Wiebe DA, Feyzi JM, Newcomb PA, Chappell RJ (1994) Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment. J Natl Cancer Inst 86: 1534-1539
30. Markopoulos C, Polychronis A, Fafarelos C, Zobolas V, Bafaloukos D, Papadiamantis J (2003) The effect of exemestane (Aromasins) on the lipidemic profile of breast cancer patients: preliminary results of the TEAM trial Greek sub-study. 26th Annual San Antonio Breast Cancer Symposium, 3-6 December 2003; San Antonio, Texas. Abstract 440
31. Matthews KA, Wing RR, Kuller LH, Meilahn EN, Plantinga P (1994) Influence of the perimenopause on cardiovascular risk factors and symptoms of middle-aged healthy women. Arch Intern Med 154: 2349-2355
32. Miller-Bass K, Newschaffer CJ, Klag MJ, Bush TL (1993) Plasma lipoprotein levels as predictors of cardiovascular death in women. Arch Intern Med 153: 2209-2216
33. Nicolaides C, Elisaf M, Bairaktari E, Kakaidi V, Katsaraki A, Pavlidis N (2000) The effect of the aromatase inhibitor letrozole on lipid parameters in postmenopausal women with breast cancer. A preliminary report. Ann Oncol 11(Suppl 4): 12 (Abstract 38 O)
34. Paridaens R, Therasse P, Dirix L, Beex L, Piccart MJ, Cameron D, Cufer T, Roozendael K, Nooy M, Mattiacci MR (2004) First results of a randomised phase III trial comparing exemestane vs tamoxifen as firstline hormone therapy (HT) for postmenopausal women with metastatic breast cancer (MBC)-EORTC 10951 in collaboration with the exemestane working group and NCIC. Fourth European Breast Cancer Conference; 16-20 March 2004; Hamburg, Germany. Abstract 241
35. Sawada S, Sato K (2003) Effect of anastrozole and tamoxifen on serum lipid levels in Japanese postmenopausal women with early breast cancer. 26th San Antonio Breast Cancer Symposium; 3-6 December 2003; San Antonio, Texas, Abstract 143
36. Schaefer EJ, Lamon-Fava S, Cohn SD, Schaefer MM, Ordovas JM, Castelli WP, Wilson PW (1994) Effects of age, gender, and menopausal status on plasma low density lipoprotein cholesterol and apolipoprotein B levels in the Framingham Offspring Study. J Lipid Res 35: 779-792
37. Stevenson JC, Crook D, Godsland IF (1993) Influence of age and menopause on serum lipids and lipoproteins in healthy women. Atherosclerosis 98: 83-90
38. Thangaraju M, Kumar K, Gandhirajan R, Sachdanandam P (1994) Effect of tamoxifen on plasma lipids and lipoproteins in postmenopausal women with breast cancer. Cancer 73: 659-663
39. Thurlimann B (2005) Letrozole as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. First results of IBCSG 18-98/BIG 1-98. Presented at the Ninth International Conference of Primary Therapy of Early Breast Cancer; 26-29 January 2005; St Gallen, Switzerland
40. Tremollieres FA, Pouilles JM, Cauneille C, Ribot C (1999) Coronary heart disease risk factors and menopause: a study in 1684 French women. Atherosclerosis 142: 415-423
41. Vrbanec D, Reiner Z, Belev B, Plestina S (1998) Changes in serum lipid and lipoprotein levels in postmenopausal patients with node-positive breast cancer treated with tamoxifen. Tumori 84: 687-690
42. Wojtacki J, Lesniewski-Kmak K, Pawlack W, Nowicka E (2004) Anastrozole therapy and lipid profile: an update. Fourth European Breast Cancer Conference; 16-20 March 2004; Hamburg, Germany. Abstract 297
43. Women’s Health Initiative Steering Committee (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. The Women’s Health Initiative randomized controlled trial. JAMA 291: 1701-1712